Upward Health Announces Contract with Clover Health to Serve Patients In Four States Under New Direct…
Austin, Texas — Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, announced today $16 million in Series B funding led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC, Excelerate Health Ventures and all existing Series A investors including Shumway Capital.
“In a short time Elligo has clearly shown that their approach improves access to clinical trials,” said John Crumpler, general partner at Hatteras Venture Partners. “We believe they will build on their current successes and continue to drive positive changes in the health care industry.”
“Our programs speak specifically to the medical practices that are hesitant to perform research in their offices due to lack of resources and infrastructure,” said John Potthoff, Ph.D., CEO of Elligo. “The new funding will help us expand our services and not only make research studies more accessible to physician sites but also streamline data collection and submission processes.”
“We look for opportunities to support entrepreneurs who excel within their industries,” said Allen Moseley, managing general partner at Noro-Moseley Partners. “Elligo’s team has the drive to effect change and the expertise to develop robust processes and technologies to significantly improve the clinical trial process.”
“The investment will enable us to accelerate expansion of our network of physicians and refine our technology platform to improve study efficiency,” said Chad Moore, president of Elligo. “And, every day we are one step — one study, one patient, one physician — closer to fulfilling our mission of improving clinical research and bringing new treatments to market faster by making it easier for physicians and patients to participate.”
Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes Direct™ with an approach that uses electronic health records and other health data to identify real-world patients and physicians for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.